SEPHS2

Across TCGA pan-cancer cohorts, SEPHS2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SEPHS2 data layer compared with 22 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher SEPHS2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated SEPHS2 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, CCRCC, and LUAD are the cancer types where SEPHS2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.509	0.312	<.001	54	view →
CCRCC	OS	Quartile	All	0.933	0.647	.004	40	view →
LUAD	OS	Tertile	All	0.987	0.494	<.001	33	view →
HNSC	DFS	Tertile	IV	0.478	0.894	<.001	28	view →
LSCC	DFS	Tertile	III,IV	0.320	0.774	.020	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SEPHS2–PDAC (DFS)

Open the PDAC breakdown →